Lindsey Stevens

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

Peter Johnson, Massimo Federico, Amy A. Kirkwood et al. · New England Journal of Medicine · 2016 · 798 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · The Lancet Oncology · 2014 · 388 citations

Medicine, Oncology, Pharmacotherapy +8

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

Sally F. Barrington, Amy A. Kirkwood, Antonella Franceschetto et al. · Blood · 2016 · 185 citations · Full text

Medicine, Oncology, Radiology +16

RESPONSE‐ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE‐ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033).

Judith Trotman, Alexander Fosså, Massimo Federico et al. · Hematological Oncology · 2017 · 28 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

Heather E. Eve, David C. Linch, Wendi Qian et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 24 citations

Medicine, Hematology, Oncology +13